From GlobeNewswire: 2025-06-17 14:55:00

Eyenovia, Inc. announced a $50 million private placement in public equity with institutional accredited investors to build a reserve of HYPE tokens from the Hyperliquid blockchain. Hyunsu Jung was appointed as Chief Investment Officer and Board Member. The Company plans to issue non-voting convertible preferred stock and warrants, expecting aggregate gross proceeds of approximately $150 million. Eyenovia aims to become one of the top validators for Hyperliquid and the first to be listed on Nasdaq. The Company will also focus on developing the Gen-2 Optejet User Filled Device for FDA registration by September 2025. The offering is expected to close on June 20, 2025, with a name change to “Hyperion DeFi” and ticker change to “HYPD.” Nasdaq Rule 5635(c)(4) Notice was provided for an inducement grant of 500,000 shares of common stock to Mr. Jung. HYPE is the 12th-largest cryptocurrency by market capitalization and provides trading fee discounts and other utilities on the Hyperliquid blockchain. Eyenovia is a digital ophthalmic technology company building a strategic treasury of HYPE tokens and developing the Optejet User Filled Device for various eye treatments. Forward-looking statements caution investors about potential risks and uncertainties related to clinical trials, market conditions, regulatory approvals, and competitive position. Eyenovia does not undertake any obligation to update forward-looking statements. For more information, visit Eyenovia.com. Investor contact: Eric Ribner, LifeSci Advisors, LLC, [email protected], (646) 751-4363.



Read more at GlobeNewswire: Eyenovia Announces $50 Million Investment to Launch a